Abstract: This invention provides 7-deoxy-taxol analogs of Formula I: The compounds of Formula I (including II and III) are useful for the same cancers for which taxol has been shown active, including human ovarian cancer, breast cancer, and malignant melanoma as well as lung cancer, gastric cancer, colon cancer, head and neck cancer, and leukemia.

Abstract: This application discloses novel tetronic acids for the treatment of AIDS and other diseases caused by retroviruses.

Abstract: This invention comprises novel substituted tetronic acid type compounds, 2, 4(3H, 5H)-furandiones, that are useful for the inhibition of the HIV protease enzyme. The compounds may be useful for the treatment of a person with AIDS or AIDS related diseases. The compounds may be used in the attempt to retard the further replication of any retrovirus containing the aspartyl protease enzyme. Compounds are represented by the formula below.

Abstract: This invention provides oxazolidine protected taxol analogs of the Formula: ##STR1## which are useful intermediates to make various taxol analogues.

Abstract: This invention provides 7-deoxy-.DELTA..sup.6,7 -taxol and 7-deoxy-.DELTA..sup.6,7 -taxol analogs of Formula I: ##STR1## The compounds of Formula I are useful for the same cancers for which taxol has been shown active, including human ovarian cancer, breast cancer, and malignant melanoma as well as lung cancer, gastric cancer, colon cancer, head and neck cancer, and leukemia.

Abstract: 6-Aryl pyrimidinol compounds, also can be named 6-aryl pyrimidinone or 6-aryl-isocytosine novel compounds, also novel and old compounds useful for treating viral infections and inducing interferon production. Dosage forms and method of treatment are disclosed.

Abstract: Disclosed are .DELTA..sup.9(11) -steroids of the formula ##STR1## which have been found to be angiostatic and therefore are useful in the control of embryogenesis, inflammatory conditions, tumor growth as well as other abnormalities.

Abstract: This invention describes the synthesis and anti-neoplastic use of 4-aziridyl-5-substituted/unsubstituted 6-aryl-pyrimidine compounds of Formula IA ##STR1## as well as N'-[2-(1-aziridyl)ethyl]-6-aryl-2,4-pyrimidinediamines of Formula IB ##STR2## and 4-chloro or bromo-5-substituted/unstubstituted-6-aryl-pyrimidines.

Abstract: A process for treating hypertension comprising the systemic administering to a hypertensive subject or a novel compound of the formula: ##STR1## wherein X is alkyl of from 1 to 3 carbon atoms, inclusive, or alkenyl of from 3 to 5 carbon atoms, inclusive.R.sub.1 is --NH.sub.2.R.sub.2 is chloro, bromo, or iodo.R.sub.3 is hydrogen or fluorine.R.sub.4 is hydrogen or fluorine, andR.sub.5 is hydrogen, fluorine, or CH.sub.3 ; or salt thereof, in association with a pharmaceutical carrier.The amount administered is from 0.1 mg to 400 mg/kg of body weight, dosage unit form and dosage amounts disclosed.

Abstract: This invention relates to the use of 6-aryluracils as antiinflammatory and antiarthritic agents and also to both novel intermediates and novel processes for the preparation of selected 6-aryluracils.

Abstract: This invention relates to the use of 6-aryluracils as antiinflammatory and antiarthritic agents and also to both novel intermediates and novel processes for the preparation of selected 6-aryluracils.

Abstract: This invention relates to the use of 6-aryluracils as antiinflammatory and antiarthritic agents and also to both novel intermediates and novel processes for the preparation of selected 6-aryluracils.

Abstract: This invention relates to the use of 6-aryluracils as antiinflammatory and antiarthritic agents and also to both novel intermediates and novel processes for the preparation of selected 6-aryluracils.

Abstract: A process for treating viral diseases in humans and animals which comprises administering a therapeutic amount of a compound of the formula ##STR1## the compounds are formulated with pharmaceutical carriers for systemic or local means of administration.

Abstract: A process for treating hypertension comprising the systemic administering to a hypertensive subject or a novel compound of the formula: ##STR1## wherein X is alkyl of from 1 to 3 carbon atoms, inclusive, or alkenyl of from 3 to 5 carbon atoms, inclusive.R.sub.1 is --NH.sub.2.R.sub.2 is chloro, bromo, or iodo.R.sub.3 is hydrogen or fluorine.R.sub.4 is hydrogen or fluorine, andR.sub.5 is hydrogen, fluorine, or CH.sub.3 ; or salt thereof, in association with a pharmaceutical carrier.The amount administered is from 0.1 mg to 400 mg/kg of body weight, dosage unit form and dosage amounts disclosed.

Abstract: Novel 5,6-dihydro-syn(s)-triazine nucleosides and nucleotides and a novel process for preparing the same. The novel nucleosides and nucleotides are disclosed as active in vitro and/or in vivo against susceptible DNA viruses.

Abstract: A process for treating hypertension comprising the systemic administering to a hypertensive subject a compound of the formula: ##STR1## wherein R.sub.1 is --NH.sub.2.R.sub.2 is chloro, bromo, or iodo.R.sub.3 is hydrogen or fluorine.R.sub.4 is hydrogen or fluorine, andR.sub.5 is hydrogen, fluorine, or CH.sub.3 ; or the salts thereof in association with a pharmaceutical carrier.

Abstract: A process for treating DNA viral diseases in humans and animals which comprises administering a therapeutic amount of a compound of the formula ##STR1## the compounds are formulated with pharmaceutical carriers for systemic or local means of administration.

Abstract: Novel 5,6-dihydro-syn(s)-triazine nucleosides and nucleotides and a novel process for preparing the same. The novel nucleosides and nucleotides are disclosed as active in vitro and/or in vivo against susceptible DNA viruses.

Abstract: Some new 1-(2- or 3-deoxy-.beta.-D-pentofuranosyl)-2-thiouracils and 1-.beta.-D-pentofuranosyl-2-thio-6-azauracils have been prepared. Further, it has been found that the known nucleoside compound, 1-.beta.-D-ribofuranosyl-2-thiouracil is active against Herpes virus and against L-1210 leukemia in mice. An improved method of preparing corresponding 2-0-methyluracil and 2-0-methyl-6-azauracil intermediates is described. The method preserves the .beta.-configuration of the starting nucleoside.